FRT vs TCRX · rev $1.28B vs rev $2.0M
FRT (FRT) versus Tscan Therapeutics Inc (TCRX) — a side-by-side from cached financials, not a winner call.
FRT (FRT) common stock.
Tscan Therapeutics Inc (TCRX) is a biotechnology company listed on NASDAQ.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
Latest reported TCRX revenue for 2026-06-30 was $2.0M. Net income was -$59.0M. TCRX currently screens at market cap $62.1M.
FRT currently screens at market cap $0. TCRX currently screens at market cap $62.1M.
Not investment advice. Open the FRT and TCRX stock pages for the full models.
Not investment advice.